신창메디칼

비상장계속사업자

shin chang medical.co,.ltd

김용창

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

신창메디칼

Business Reg. No. 5138113825 · CEO 김용창

I.Investment Overview

Target신창메디칼 (5138113825)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명신창메디칼
영문명shin chang medical.co,.ltd
대표자김용창
사업자등록번호5138113825
법인등록번호1760110016912
설립일1998.07.13

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW296.52021355.52022370.12023401.82024445.72025
영업이익100M KRW45.6202147.8202236202358.2202475.62025
순이익100M KRW50.2202149.6202233.1202358.9202469.42025
Item20252024202320222021
자산총계608.1억원534.6억원467.5억원481.8억원466.8억원
부채총계166.6억원155.7억원147.5억원196.9억원231.6억원
자본총계441.5억원378.9억원320억원284.8억원235.2억원
매출액445.7억원401.8억원370.1억원355.5억원296.5억원
영업이익75.6억원58.2억원36억원47.8억원45.6억원
순이익69.4억원58.9억원33.1억원49.6억원50.2억원

VI.Financial Ratios

FY2025 basis

16.96%

영업이익률

15.58%

순이익률

11.42%

ROA

15.73%

ROE

37.74%

부채비율

72.6%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

신창메디칼 투심보고서 | Alpha Lenz